UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 3)*
PharmaCyte Biotech, Inc.
(Name
of Issuer)
Common Stock, $0.0001 par value per share
(Title
of Class of Securities)
717512X203
(CUSIP
Number)
December 31, 2023
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
* | The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page. |
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
1. |
Names
of Reporting Persons. |
|
|
|
Mitchell
P. Kopin |
|
|
|
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) ☐ |
|
(b) ☐ |
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
4. |
Citizenship
or Place of Organization United States of America |
|
|
Number
of
Shares Beneficially
Owned by Each
Reporting Person
With: |
5. Sole
Voting Power |
0 |
|
|
|
|
6. Shared
Voting Power |
903,412
|
|
|
|
|
7. Sole
Dispositive Power |
0 |
|
|
|
|
8. Shared
Dispositive Power |
903,412
|
|
|
9. |
Aggregate Amount Beneficially
Owned by Each Reporting Person 903,412 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions) ☐ |
|
|
|
|
11. |
Percent of Class Represented by Amount in Row
(9) 9.99% (see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
IN;
HC |
1. |
Names of Reporting Persons. |
|
|
|
Daniel B. Asher
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) ☐ |
|
(b) ☐ |
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
4. |
Citizenship or Place of Organization United
States of America |
|
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
With: |
5. Sole Voting Power |
82,727 |
|
|
|
|
6. Shared Voting Power |
811,503
|
|
|
|
|
7. Sole Dispositive Power |
82,727 |
|
|
|
|
8. Shared Dispositive Power |
811,503
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting
Person 894,230 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐ |
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) 9.99%
(see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
IN; HC |
1. |
Names of Reporting Persons. |
|
|
|
Intracoastal Capital LLC
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) ☐ |
|
(b) ☐ |
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
4. |
Citizenship or Place of Organization Delaware |
|
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
With: |
5. Sole Voting Power |
0 |
|
|
|
|
6. Shared Voting Power |
903,412
|
|
|
|
|
7. Sole Dispositive Power |
0 |
|
|
|
|
8. Shared Dispositive Power |
903,412
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person 903,412 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐ |
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) 9.99%
(see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
OO |
This Amendment No. 3 is being filed jointly by the Reporting Persons
and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”)
on August 30, 2021, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 11, 2022, and as amended
by Amendment No. 2 thereto filed by the Reporting Persons with the SEC on February 8, 2023 (the “Schedule 13G”).
Except as set forth below,
all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed
to such terms in the Schedule 13G.
Item 4. Ownership.
(a) and (b):
As of the close of business on December 31, 2023, each of Intracoastal
and Mr. Kopin may have been deemed to have beneficial ownership of 903,412 shares of Common Stock, which consisted of (i) 475,884 shares
of Common Stock held by Intracoastal and (ii) 427,528 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal
(“Intracoastal Warrant 1”), and all such shares of Common Stock represented beneficial ownership of approximately 9.99%
of the Common Stock, based on (1) 8,615,640 shares of Common Stock outstanding as of December 13, 2023, as reported by the Issuer, plus
(2) 427,528 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 72,472 shares of Common
Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder
thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result
in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together
with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 129,147 shares of Common Stock issuable
upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains
a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only
to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates,
and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common
Stock, (III) 2,312,500 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant
3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise
Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof,
together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s
affiliates, of more than 4.99% of the Common Stock and (IV) 2,119,792 shares of Common Stock issuable upon conversion of 8,4719.17 shares
of Series B Convertible Preferred Stock (the “Series B Preferred Stock”) held by Intracoastal because the terms of
the Series B Preferred Stock contain a blocker provision under which the holder thereof does not have the right to convert the Series
B Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership by the holder thereof,
together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s
affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of Intracoastal and Mr. Kopin may have been
deemed to have beneficial ownership of 5,537,323 shares of Common Stock.
As of the close of
business on December 31, 2023, Mr. Asher may have been deemed to have beneficial ownership of 894,230 shares of Common Stock, which consisted
of (i) 475,884 shares of Common Stock held by Intracoastal, (ii) 82,727 shares of Common Stock held by Mr. Asher and (iii) 335,619 shares
of Common Stock issuable upon exercise Intracoastal Warrant 1, and all such shares of Common Stock represented beneficial ownership of
approximately 9.99% of the Common Stock, based on (1) 8,615,640 shares of Common Stock outstanding as of December 13, 2023, as reported
by the Issuer, plus (2) 335,619 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 164,381
shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under
which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such
exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons
acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 625,000
shares of Common Stock issuable upon exercise of a warrant held by Mr. Asher (the “Asher Warrant”) because Asher Warrant
contains a blocker provision under which the holder thereof does not have the right to exercise the Asher Warrant to the extent (but
only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates,
and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common
Stock, (III) 572,918 shares of Common Stock issuable upon conversion of 2,291.67 shares of Series B Preferred Stock held by Mr. Asher
because the terms of the Series B Preferred Stock contain a blocker provision under which the holder thereof does not have the right
to convert the Series B Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership
by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder
or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 129,147 shares of Common Stock issuable upon exercise
of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the
right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership
by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder
or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (V) 2,312,500 shares of Common Stock issuable upon exercise
of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the
right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership
by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder
or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (VI) 2,119,792 shares of Common Stock issuable upon
conversion of 8,4719.17 shares of Series B Preferred Stock held by Intracoastal because the terms of the Series B Preferred Stock contain
a blocker provision under which the holder thereof does not have the right to convert the Series B Preferred Stock to the extent (but
only to the extent) that such conversion would result in beneficial ownership by the holder thereof, together with the holder’s
affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99%
of the Common Stock. Without such blocker provisions, Mr. Asher may have been deemed to have beneficial ownership of 6,817,968 shares
of Common Stock.
(c) Number of shares as to
which Intracoastal and Mr. Kopin has:
(i) Sole power to vote or to direct the vote: 0 .
(ii) Shared power to vote or to direct the vote: 903,412 .
(iii) Sole power to dispose or to direct the disposition
of 0 .
(iv) Shared power to dispose or to direct the disposition
of 903,412 .
Number of shares as to which
Mr. Asher has:
(i) Sole power to vote or to direct the vote: 82,727 .
(ii) Shared power to vote or to direct the vote: 811,503 .
(iii) Sole power to dispose or to direct the disposition
of 82,727 .
(iv) Shared power to dispose or to direct the disposition
of 811,503 .
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 6, 2024
|
/s/ Mitchell P. Kopin |
|
Mitchell P. Kopin |
|
|
|
/s/ Daniel B. Asher |
|
Daniel B. Asher |
|
|
|
Intracoastal Capital LLC |
|
|
|
By: |
/s/ Mitchell P. Kopin |
|
|
Mitchell P. Kopin, Manager |
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Dec 2024 to Jan 2025
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Jan 2024 to Jan 2025